Related references
Note: Only part of the references are listed.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy
R. E. Pratley et al.
DIABETES OBESITY & METABOLISM (2009)
Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects
Ronald Christopher et al.
CLINICAL THERAPEUTICS (2008)
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptino: A randomized, double-mind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes
Paul Covington et al.
CLINICAL THERAPEUTICS (2008)
Pioglitazone and sulfonylureas: effectively treating type 2 diabetes
M. Hanefeld
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2007)
Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV
Jun Feng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects
Goutam C. Mistry et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Pioglitazone - A review of its use in type 2 diabetes mellitus
J Waugh et al.
DRUGS (2006)
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone
T Jaakkola et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Drug therapy: Thiazolidinediones
H Yki-Jarvinen
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Inhibitory effect of glyburide on human cytochrome P450 isoforms in human liver microsomes
KA Kim et al.
DRUG METABOLISM AND DISPOSITION (2003)
Pharmacokinetics and pharmacodynamics of extended-release glipizide GITS compared with immediate-release glipizide in patients with type II diabetes mellitus
M Chung et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2002)